Listen in as our expert panel tackles real-world questions about GLP-1 agonists, from starting them and setting expectations with patients to strategies for switching agents. You’ll also hear them review key considerations to limit muscle loss with GLP-1 agonist use and discuss why some patients hit a plateau or don’t respond to GLP-1 agonists.
Special guests:
Jennifer N. Clements, PharmD, FCCP, FADCES, BCPS, BCACP, CDCES, BC-ADM
Clinical Professor and Director of Pharmacy Education
University of South Carolina College of Pharmacy
Jennifer M. Trujillo, PharmD, BCPS, FCCP, CDCES, BC-ADM
Professor and the Associate Dean for Education
University of Colorado Skaggs School of Pharmacy and Pharmaceutical Sciences
Panelists on TRC’s Editorial Advisory Board:
Stephen Carek, MD, CAQSM, DipABLM
Clinical Associate Professor of Family Medicine
Prisma Health/USC-SOMG Family Medicine Residency Program
USC School of Medicine Greenville
Craig D. Williams, PharmD, FNLA, BCPS
Clinical Professor of Pharmacy Practice
Oregon Health and Science University
For the purposes of disclosure Dr. Jennifer Clements reports relevant financial relationships with Novo Nordisk (Ozempic, Rybelsus), Eli Lilly (Zepbound, tirzepatide) [speakers bureau].
The other speakers have nothing to disclose. All relevant financial relationships have been mitigated.
This podcast is an excerpt from one of TRC’s monthly live CE webinars, the full webinar originally aired in February 2026.
TRC Healthcare offers CE credit for this podcast. Log in to your Pharmacist’s Letter, Pharmacy Technician’s Letter,or Prescriber Insights account and look for the title of this podcast in the list of available CE courses.
Podden och tillhörande omslagsbild på den här sidan tillhör
TRC Healthcare | Pharmacist's Letter | Prescriber Insights | Pharmacy Technician's Letter. Innehållet i podden är skapat av TRC Healthcare | Pharmacist's Letter | Prescriber Insights | Pharmacy Technician's Letter och inte av,
eller tillsammans med, Poddtoppen.